Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
QuidelOrtho Corporation filings document an in vitro diagnostics company with Nasdaq-listed common stock under QDEL. Form 8-K disclosures cover quarterly and annual operating results, preliminary revenue estimates, financial guidance, Regulation FD communications and business commentary tied to point-of-care, labs, respiratory, cardiac and immunohematology diagnostics.
The company’s proxy and governance filings address annual meeting matters, board composition, executive compensation and shareholder voting information. Other current reports record leadership transitions, director changes, registered securities information and exhibit-based disclosures furnished with earnings releases and stockholder communications.
QuidelOrtho Corp executive Bryan Michael Hanson reported routine equity compensation and related tax withholding. On April 22, 3,508 restricted stock units previously reported on a Form 3 were released and converted into 3,508 shares of common stock. To cover tax withholding obligations, 1,269 shares were disposed of through the issuer’s share withholding at $11.90 per share, rather than an open‑market sale. Following these transactions, Hanson directly held 4,408 common shares. An additional 3,508 restricted stock units remain scheduled to vest on April 22, 2027, each representing the right to receive one share of QuidelOrtho common stock.
SISITSKY NATHANIEL reported acquisition or exercise transactions in this Form 4 filing.
QuidelOrtho Corp granted its Chief Legal Officer, Nathaniel Sisitksy, new equity awards reported as compensation. He received 73,434 non-qualified stock options exercisable at $17.49 per share, expiring on April 15, 2036, covering 73,434 shares of common stock. He was also granted 73,435 restricted stock units, each representing one share of common stock. For these awards, 24,478 shares are scheduled to vest in equal installments on April 15, 2027 and April 15, 2028, with 24,479 shares vesting on April 15, 2029, and another schedule provides 24,478 shares vesting in equal installments on April 15, 2027, April 15, 2028 and April 15, 2029.
QuidelOrtho Corporation released preliminary unaudited results showing first quarter 2026 revenue of $615–$620 million, reflecting a weaker respiratory season, slower distributor sales in China tied to proposed reimbursement cuts, and EMEA order delays related to the Middle East conflict.
The company expects first quarter 2026 free cash flow of $(65) to $(70) million and continues to anticipate positive free cash flow for full-year 2026. Management believes the low end of its previously issued full-year 2026 financial guidance remains achievable and plans to discuss this outlook with full results on May 5, 2026.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 5,629,965 shares of QuidelOrtho Corp common stock, equal to 8.3% of the class. The filing lists 5,612,705 shares with sole voting power and 5,629,965 shares with sole dispositive power. The amendment is signed by a Vice President and dated 04/08/2026.
QuidelOrtho Corp executive Nathaniel Sisitsky, the Chief Legal Officer, has filed an initial ownership report indicating that he currently holds no securities beneficially owned in the company. The filing shows total direct holdings of 0 shares following the reported position.
QuidelOrtho Corp Chief Financial Officer Joseph M. Busky reported routine equity compensation activity involving restricted stock units and related tax withholding. On the transaction date, 4,925 restricted stock units were released, converting into 4,925 shares of common stock as part of previously reported awards.
Of these shares, 1,519 were withheld by the company at $14.78 per share to satisfy tax withholding obligations tied to the RSU release, which is not an open-market sale. Following these transactions, Busky held 44,818 shares of common stock directly and 10,290 shares indirectly through a trust.
QuidelOrtho Corp received an amended Schedule 13G/A from The Vanguard Group stating that, following an internal realignment, Vanguard reports 0 shares beneficially owned of QuidelOrtho common stock.
The filing explains certain subsidiaries will report disaggregated ownership separately in reliance on SEC Release No. 34-39538.
QuidelOrtho Corp executive vice president Bryan Michael Hanson filed an initial ownership report showing existing equity awards rather than new trades. He directly holds multiple incentive and non-qualified stock options on common stock with exercise prices ranging from $27.17 to $179.06, plus several restricted stock unit grants, including one for 36,152 underlying shares, and 900 common shares. Footnotes detail vesting schedules through dates such as July 1, 2028 and January 30, 2029, with each restricted stock unit convertible into one common share.
QuidelOrtho Corporation announced a planned leadership transition in its top legal role. Chief Legal Officer and Corporate Secretary Michelle A. Hodges will retire from these positions effective March 23, 2026, with a transition and retirement agreement supporting an orderly handover of her duties.
For up to six months, Ms. Hodges will continue receiving her current base salary and benefits while transitioning responsibilities. She will then serve as special advisor to the Chief Executive Officer for up to twenty-four months, initially at her current base salary rate, which will be reduced by 50% for the remainder of the advisory term, while remaining eligible for employee benefits, annual bonus and equity grant opportunities, and continued vesting of existing equity awards.
The Board of Directors appointed Nathaniel “Nate” Sisitsky as the new Chief Legal Officer and Corporate Secretary, effective as of the same date. With more than 25 years of legal and governance experience at public life sciences and technology companies, including prior Chief Legal Officer and Corporate Secretary roles, he will lead QuidelOrtho’s global legal, compliance and corporate governance functions.
QuidelOrtho Corp’s Chief Financial Officer Joseph M. Busky reported an amended insider transaction reflecting an open-market purchase of 3,370 shares of common stock on February 13, 2026, acquired indirectly through a trust at a weighted average price of $23.6623 per share.
The amendment corrects the pricing details, noting a purchase price range from $23.0150 to $23.6750 per share. Following these transactions, Busky’s indirect holdings held by a trust total 10,290 shares, and his direct ownership stands at 41,412 shares of QuidelOrtho common stock.